JP2008531672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531672A5 JP2008531672A5 JP2007557589A JP2007557589A JP2008531672A5 JP 2008531672 A5 JP2008531672 A5 JP 2008531672A5 JP 2007557589 A JP2007557589 A JP 2007557589A JP 2007557589 A JP2007557589 A JP 2007557589A JP 2008531672 A5 JP2008531672 A5 JP 2008531672A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- microparticle composition
- microparticle
- ssrna
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011859 microparticle Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 239000000839 emulsion Substances 0.000 claims description 14
- 239000003381 stabilizer Substances 0.000 claims description 14
- 229920002988 biodegradable polymer Polymers 0.000 claims description 8
- 239000004621 biodegradable polymer Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 238000012792 lyophilization process Methods 0.000 claims description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical group CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000002689 Toll-like receptor Human genes 0.000 claims 3
- 108020000411 Toll-like receptor Proteins 0.000 claims 3
- 230000000840 anti-viral effect Effects 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical group [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710194807 Protective antigen Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229920003232 aliphatic polyester Polymers 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 239000000243 solution Substances 0.000 description 6
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000011488 interferon-alpha production Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0504276A GB0504276D0 (en) | 2005-03-02 | 2005-03-02 | Pharmaceutical composition |
| GB0511801A GB0511801D0 (en) | 2005-06-10 | 2005-06-10 | Pharmaceutical composition |
| PCT/GB2006/000751 WO2006092607A1 (en) | 2005-03-02 | 2006-03-02 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531672A JP2008531672A (ja) | 2008-08-14 |
| JP2008531672A5 true JP2008531672A5 (enExample) | 2009-04-16 |
Family
ID=36353665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557589A Pending JP2008531672A (ja) | 2005-03-02 | 2006-03-02 | 医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080138431A1 (enExample) |
| EP (1) | EP1853227B1 (enExample) |
| JP (1) | JP2008531672A (enExample) |
| AT (1) | ATE438385T1 (enExample) |
| AU (1) | AU2006219717B2 (enExample) |
| CA (1) | CA2599329A1 (enExample) |
| DE (1) | DE602006008278D1 (enExample) |
| WO (1) | WO2006092607A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4846200B2 (ja) | 2002-04-04 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫賦活性ｇ、ｕ含有オリゴリボヌクレオチド |
| EP2883957A1 (en) | 2005-11-25 | 2015-06-17 | Zoetis Belgium S.A. | Immunostimmulatory oligoribonucleotides |
| AU2009241645B2 (en) * | 2008-05-02 | 2014-07-17 | Blink Therapeutics Limited | Products and methods for stimulating an immune response |
| RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| PT2590626E (pt) | 2010-07-06 | 2016-01-26 | Glaxosmithkline Biolog Sa | Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| HUE058361T2 (hu) | 2010-08-31 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNA bejuttatására |
| ES2945135T3 (es) | 2010-10-11 | 2023-06-28 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
| BR0213119A (pt) * | 2001-10-03 | 2004-12-28 | Chiron Corp | Composição imunogênica e uso da mesma |
| WO2004062599A2 (en) * | 2003-01-06 | 2004-07-29 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| AU2004225480A1 (en) * | 2003-03-26 | 2004-10-14 | Multicell Immunotherapeutics, Inc. | Selected RNA motifs to include cell death and/or apoptosis |
-
2006
- 2006-03-02 DE DE602006008278T patent/DE602006008278D1/de active Active
- 2006-03-02 AT AT06709975T patent/ATE438385T1/de not_active IP Right Cessation
- 2006-03-02 AU AU2006219717A patent/AU2006219717B2/en not_active Ceased
- 2006-03-02 JP JP2007557589A patent/JP2008531672A/ja active Pending
- 2006-03-02 US US11/885,538 patent/US20080138431A1/en not_active Abandoned
- 2006-03-02 WO PCT/GB2006/000751 patent/WO2006092607A1/en not_active Ceased
- 2006-03-02 EP EP06709975A patent/EP1853227B1/en not_active Not-in-force
- 2006-03-02 CA CA002599329A patent/CA2599329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ho et al. | Next‐generation vaccines: nanoparticle‐mediated DNA and mRNA delivery | |
| Zeng et al. | Formulation and delivery technologies for mRNA vaccines | |
| Chen et al. | Advances in the polymeric delivery of nucleic acid vaccines | |
| Hanagata | Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system | |
| Zhao et al. | Enhancing mucosal immune response of Newcastle disease virus DNA vaccine using N-2-hydroxypropyl trimethylammonium chloride chitosan and N, O-carboxymethyl chitosan nanoparticles as delivery carrier | |
| Qin et al. | Recent advances in the noninvasive delivery of mRNA | |
| CN101874112A (zh) | 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸 | |
| Andrianov et al. | Supramolecular assembly of Toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo | |
| Andresen et al. | Nucleic acid delivery and nanoparticle design for COVID vaccines | |
| AU2003219805B2 (en) | Electroporation methods for introducing bioactive agents into cells | |
| JP2008531672A5 (enExample) | ||
| Collier et al. | Delivery of host cell-directed therapeutics for intracellular pathogen clearance | |
| CN118001254B (zh) | 靶向抗原呈递细胞的脂质组合物及其应用 | |
| EP1853227B1 (en) | Pharmaceutical composition | |
| Carmona-Ribeiro | Cationic nanostructures for vaccines | |
| Pereira et al. | Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review | |
| US12064511B2 (en) | Lipid nanoparticles containing silyl lipids for use in vaccines and gene therapy | |
| Luo et al. | Unlocking Delivery Strategies for mRNA Therapeutics | |
| Hussain et al. | Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement: Nanoparticle-Mediated Mucosal Vaccination | |
| Zhou et al. | Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly | |
| Kirtane et al. | Improving the Efficacy of Cancer mRNA Vaccines | |
| Das et al. | Emerging concepts in Leishmania vaccine adjuvants | |
| Xin et al. | mRNA-Based Cancer Therapy and Challenges | |
| Del Bene et al. | From genetic code to global health: the impact of nucleic acid vaccines on disease prevention and treatment | |
| Duc | Immune Response Activation |